Real-world utilization of PD-1/PD-L1 inhibitors with palliative radiotherapy in patients with metastatic non-small cell lung cancer.
Zi-Chao ZhouKai-Yan ChenNa LiMing-Ying XieJia-Min ShengYun FanZhi-Yu HuangPublished in: Thoracic cancer (2022)
The combination of PD-1/PD-L1 inhibitors plus palliative radiotherapy demonstrated favorable survival and good tolerability in metastatic NSCLC patients.
Keyphrases
- small cell lung cancer
- end stage renal disease
- early stage
- palliative care
- radiation therapy
- chronic kidney disease
- newly diagnosed
- squamous cell carcinoma
- locally advanced
- radiation induced
- advanced cancer
- peritoneal dialysis
- prognostic factors
- open label
- randomized controlled trial
- patient reported outcomes
- epidermal growth factor receptor